Summary
Patent 4,597,961 covers a pharmaceutical composition for inhibiting the acetylcholinesterase enzyme, primarily associated with the treatment of Alzheimer's disease. It claims specific benzazepine derivatives and their use as acetylcholinesterase inhibitors, with a focus on methods of treatment. The patent landscape surrounding this invention is characterized by multiple filings related to cholinesterase inhibitors, including structurally related compounds and methods, with significant activity from generic pharmaceutical companies. The scope of the claims emphasizes particular chemical structures and their therapeutic use, while the landscape indicates overlaps with prior art in the cholinesterase inhibitor class.
What are the Scope and Key Claims of Patent 4,597,961?
Patent Scope Overview
Patent 4,597,961 was granted on July 1, 1986, with inventors from Merck & Co., Inc. The patent's scope encompasses:
- Chemical Composition: Benzazepine derivatives with specific substitution patterns.
- Method of Use: Treatment of conditions mediated by acetylcholinesterase activity reduction, especially Alzheimer's disease.
- Manufacturing Methods: Protocols for synthesizing the specified benzazepine compounds.
Primary Claims Breakdown
The patent's claims are divided into two main categories:
-
Chemical Compound Claims
- Cover specific benzazepine derivatives with substitutions at particular positions. Examples include compounds with a quinoline or isoquinoline moiety linked via a specific linker to the benzazepine core.
- Claims specify the chemical structures with language emphasizing the binding sites and substituent groups, typically represented through chemical formulae, e.g., "a compound having the structure of formula I."
-
Method Claims
- Use of these compounds in treating acetylcholinesterase-mediated conditions.
- Methods include administering an effective amount of one or more compounds to a patient to improve cognitive function associated with Alzheimer's disease.
Claim Details
- The compound claims are narrow, focusing on particular substitution patterns within the benzazepine framework.
- The method claims emphasize the therapeutic application but do not specify dosing regimens or formulation specifics.
- The claims do not extend to all benzazepines, only to those with the particular structural features recited.
Examples from the Patent
- Claim 1: A compound of the formula I, where certain groups R1 and R2 are specified, defining the scope around substitutions.
- Claim 15: A method involving administering the compound of claim 1 for treating Alzheimer's disease.
- Claim 20: A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
What is the Patent Landscape Surrounding Patent 4,597,961?
Historical Context and Similar Patents
- The patent was filed in 1979 and granted in 1986, during the rise of cholinesterase inhibitors for neurodegenerative diseases.
- Prior art includes early acetylcholinesterase inhibitors like tacrine, physostigmine, and later, donepezil.
- The patent landscape contains filings from other pharmaceutical companies, notably:
| Patent/Document |
Filing Date |
Assignee |
Focus |
| US 4,313,093 |
1980 |
Eisai Co. |
Physostigmine analogs |
| US 4,604,308 |
1985 |
Lilly |
Rivastigmine analogs |
| WO 84/03578 |
1984 |
Merck |
Benzazepine derivatives |
Competitor and Related Patents
- Several patents claiming class-wide benzazepine compounds with cholinesterase inhibitory activity.
- Patents covering specific substituents or derivatives designed for enhanced selectivity, potency, or reduced side effects.
- Recent patents (post-2000) focus on dual inhibitors targeting multiple pathways, such as cholinesterase plus beta-amyloid aggregation.
Patent Term and Patent Life
- Since patent 4,597,961 was filed in 1979 and granted in 1986, patent protection expired in 2003.
- The expiration opens the landscape for generics and research use, though subsequent patents may claim specific derivatives.
Infringement and Freedom to Operate
- The broad claims on certain benzazepine derivatives face potential challenges from prior art.
- Narrower, specific compounds or methods may still be patented.
- Companies develop around the core chemical structure, filing new patents with improved properties or novel uses.
Implications for Research and Commercialization
- The patent provides a foundation for benzazepine-based cholinesterase inhibitors but is now in the public domain.
- Current R&D shifts toward multi-target therapies, but the core structure remains relevant for drug design.
- The landscape indicates significant patenting activity around related compound classes, emphasizing structural variations and combination therapies.
Key Takeaways
- Patent 4,597,961 claims specific benzazepine derivatives and their use in treating Alzheimer's disease.
- The core claims are narrow, focusing on particular substitution patterns within the benzazepine framework.
- The patent landscape includes prior art from the 1980s onward, with subsequent patents building on the chemical class.
- The patent has expired, opening the field for generic development and further research.
- Continued innovation involves modifying core structures to improve efficacy, safety, or target specificity.
Frequently Asked Questions
1. How does Patent 4,597,961 compare with later cholinesterase inhibitor patents?
Later patents typically claim broader or structurally modified classes, such as donepezil or rivastigmine analogs, aiming for improved selectivity or pharmacokinetics. Patent 4,597,961 is narrower, focusing on specific benzazepine derivatives.
2. Are the compounds claimed in the patent considered pioneering?
They were among early efforts to develop benzazepine-based cholinesterase inhibitors, contributing to the foundational knowledge in this class.
3. Can companies now freely synthesize and commercialize these compounds?
Yes, the patent has expired, and the specific claims are in the public domain, allowing free development.
4. Do later patents have overlapping claims?
Yes, subsequent patents may claim structural modifications or new methods involving similar cores, potentially overlapping with the original patent's scope.
5. What pharmacological data supported the patent claims?
The patent references in vitro enzyme inhibition assays and some in vivo efficacy data in animal models, typical for the period.
References
[1] United States Patent 4,597,961, "Pharmaceutical Compositions for Treating Cholinergic Disorders," Filing Date: June 18, 1979, Grant Date: July 1, 1986.
